Sat.Apr 13, 2024

article thumbnail

Opinion: Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more

STAT

STAT publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay.

271
271
article thumbnail

EMCrit Wee – Ross Prager on 10 Heuristics for the New ICU Attending

EMCrit Project

10 heuristics for the new Crit Care doc from Ross Prager EMCrit Project by Scott Weingart, MD FCCM.

87
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Patent Expirations for the Week of April 14, 2024

Drug Patent Watch

DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 8,784,885 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… Source

59
article thumbnail

Role of the Pharmacist in Institutional Readiness, Patient Readiness for Bispecifics

Pharmacy Times

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

53
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Which pharmaceutical companies have the most cream dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types.

article thumbnail

New patent for Glaxo Grp drug ADVAIR HFA

Drug Patent Watch

Annual Drug Patent Expirations for ADVAIR+HFA Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from three suppliers.

52

More Trending

article thumbnail

New patent for Gilead Sciences drug VOSEVI

Drug Patent Watch

Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Pfizer drug DAURISMO

Drug Patent Watch

Annual Drug Patent Expirations for DAURISMO Daurismo is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Astellas drug XOSPATA

Drug Patent Watch

Annual Drug Patent Expirations for XOSPATA Xospata is a drug marketed by Astellas and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Oyster Point drug TYRVAYA

Drug Patent Watch

Annual Drug Patent Expirations for TYRVAYA Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. It is available from one supplier.

52
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

New patent for Strongbridge drug RECORLEV

Drug Patent Watch

Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. It is available from one supplier.

52